17:30 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) Cell culture and mouse studies suggest phenformin could help treat PTEN-deficient T cell ALL. In three mouse PTEN-deficient T cell ALL cell lines, phenformin inhibited growth with...
03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
14:43 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture, patient sample and mouse studies suggest inhibiting SMARCA4 could help treat PTEN-deficient prostate cancer. Screening of a CRISPR single-guide RNA (sgRNA) library targeting 517 genes encoding epigenetic regulators in PTEN-deficient...
20:22 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...
16:49 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
23:10 , May 2, 2018 |  BC Extra  |  Preclinical News

UCSF study suggests stress response inhibitor could treat prostate cancer

A new study from University of California San Francisco researchers suggests that releasing the "brakes" on a tumor's stress regulation system by inhibiting eukaryotic translation initiation factor 2A (EIF2A) could help treat metastatic prostate cancer....
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
20:45 , Oct 31, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Serous tubal intraepithelial carcinomas (STICs) in the fallopian tubes could help predict the risk of high-grade serous ovarian carcinoma. In 37 samples of STICs, fallopian tube carcinomas, primary and/or metastatic ovarian tumors...
20:11 , Jul 27, 2017 |  BC Extra  |  Preclinical News

Group identifies S6K1 as potential target for CNS injury

In a paper published in the Journal of Neuroscience , researchers at the University of Miami Miller School of Medicine and colleagues showed that targeting ribosomal protein S6 kinase 70kDa polypeptide 1 ( RPS6KB1 ;...
21:41 , Jul 24, 2017 |  BC Extra  |  Preclinical News

Group identifies ZFN326 gene as possible TNBC target

In a paper published in Cancer Research , researchers identified four tumor suppressor genes in triple-negative breast cancer, including one whose expression may be associated with patient survival. The paper's authors included researchers from Houston...